Stocks To Buy Now

Blog


EVIO, Inc. (SGBYD) Changes Name, Adopts New Ticker Symbol and Announces a Reverse Stock Split

  • Name change to EVIO, Inc., from Signal Bay, Inc., reflects fact that EVIO Labs division generates majority of company volume
  • New ticker symbol of EVIO will become effective October 3, 2017, for the legalized cannabis industry’s quality control testing and ancillary advisory services company
  • Reverse stock split is positioned to attract institutional investors to provide funding for company’s vision of becoming a leading biotechnology firm in the cannabis industry

EVIO, Inc. (OTCQB: SGBYD) has changed its name from Signal Bay, Inc. and also announced a reverse stock split (http://dtn.fm/Set9Z). The life science company will also have a new ticker symbol, EVIO, effective October 3, 2017, pending approval. EVIO Labs provide the cannabis industry with accredited analytical testing and scientific research.

EVIO engineered the 1:100 reverse stock split in order to reduce its outstanding shares from three billion to one billion. After the split, the par value of each share of common stock remains unchanged.

We are excited about the future direction of the Company, under the new name of EVIO, Inc.,” William Waldrop, EVIO CEO, stated in a news release. “We aligned the corporate name with our EVIO Labs Division which accounts for a majority of our revenue and lays a foundation for becoming a leading cannabis biotechnology company. Furthermore, with the effectiveness of the reverse stock split, we structured the company to be best positioned for institutional investors to provide the necessary funding to complete our vision. These are exciting times to be part of the fastest growing industry in the world, and EVIO is now positioned to take full advantage of this opportunity.”

Additionally, the company has licensed its brand and cannabis technology in Colorado to Phytatech CO, LLC. Phytatech will now operate under the EVIO Labs brand (http://dtn.fm/BSrz4).

For more information, visit the company’s website at www.EVIOLabs.com

From Our Blog

Soligenix Inc. (NASDAQ: SNGX) Advances Clinical Credibility with HyBryte Research Publication

April 1, 2026

The publication of clinical research in peer-reviewed journals remains a critical milestone in drug development, offering independent validation and broader visibility for emerging therapies. Soligenix (NASDAQ: SNGX) recently reached such a milestone with the publication of a clinical summary of its HyBryte(TM) therapy, reinforcing the importance of scientific transparency as the company advances treatments for […]

Rotate your device 90° to view site.